Dicerna Pharmaceuticals downgraded by RBC Capital with a new price target

11/19/21 5:44:25 AM ET

Major Pharmaceuticals

Health Care

RBC Capital downgraded Dicerna Pharmaceuticals from Outperform to Sector Perform and set a new price target of $38.25 from $30.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DRNA

Date	Price Target	Rating	Analyst
12/9/2021	$28.00 → $38.25	Buy → Neutral	Chardan Capital
11/19/2021	$30.00 → $38.25	Outperform → Sector Perform	RBC Capital
11/18/2021	$32.00 → $38.25	Buy → Neutral	HC Wainwright & Co.
8/11/2021	$36.00 → $25.00	Buy → Neutral	Goldman Sachs
8/10/2021	$34.00 → $28.00	Buy	Chardan Capital
8/10/2021	$38.00 → $32.00	Buy	HC Wainwright & Co.
8/9/2021	$32.00	Buy → Neutral	Citigroup
8/6/2021	$35.00 → $30.00	Outperform	RBC Capital